Cargando…

Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation

Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication that occurs after hematopoietic cell transplantation (HCT). The mortality associated with untreated VOD/SOS with multiorgan dysfunction (MOD) has been reported to be >80%. The r...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Paul G., Smith, Angela R., Kernan, Nancy A., Lehmann, Leslie, Ryan, Robert J., Grupp, Stephan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549529/
https://www.ncbi.nlm.nih.gov/pubmed/32950693
http://dx.doi.org/10.1016/j.bbmt.2020.09.008
_version_ 1784590798838300672
author Richardson, Paul G.
Smith, Angela R.
Kernan, Nancy A.
Lehmann, Leslie
Ryan, Robert J.
Grupp, Stephan A.
author_facet Richardson, Paul G.
Smith, Angela R.
Kernan, Nancy A.
Lehmann, Leslie
Ryan, Robert J.
Grupp, Stephan A.
author_sort Richardson, Paul G.
collection PubMed
description Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication that occurs after hematopoietic cell transplantation (HCT). The mortality associated with untreated VOD/SOS with multiorgan dysfunction (MOD) has been reported to be >80%. The recommended dose of defibrotide is 6.25 mg/kg every 6 hours, administered as a 2-hour i.v. infusion, for a minimum of 21 days or until resolution of VOD/SOS signs and symptoms. The objective of this analysis was to evaluate the time to complete response (CR) in patients with post-HCT VOD/SOS treated with defibrotide. The time to defibrotide discontinuation due to a CR served as a surrogate for time to CR in an expanded access study (T-IND; ClinicalTrials.gov NCT00628498; n = 1000), and was analyzed separately from the time to CR data pooled from a phase 2 randomized dose-finding study (NCT00003966; n = 74 patients who received 25 mg/kg/day) and a phase 3 historically controlled study (NCT00358501; n = 102). For all studies, a CR was defined as total serum bilirubin <2 mg/dL with resolution of VOD/SOS-related MOD (renal and/or pulmonary dysfunction); the phase 2 study also required resolution of central nervous system dysfunction. In the T-IND, 390 patients discontinued treatment due to a CR and had sufficient data for analysis. The median time to discontinuation was 22 days (range, 2 to 64 days). Discontinuation due to CR occurred beyond 21 days in 235 patients (60%) and beyond 28 days in 57 patients (15%). The pooled phase 2 and 3 studies included 60 patients who achieved a CR, with a median time to CR of 24.5 days (range, 7 to 123 days). A CR was achieved beyond 21 days in 32 patients (53%) and beyond 28 days in 24 patients (40%). The Kaplan-Meier estimate of day +100 survival rate was substantially higher in patients who discontinued due to a CR compared with those who did not (92.5% versus 37.3%). Treatment-emergent adverse events occurred in 185 of 390 patients (47%) who discontinued due to a CR in the T-IND and in 55 of 60 patients (92%) who achieved a CR in the pooled phase 2 and 3 studies, and rates did not differ according to duration of treatment (≤21 days versus >21 days). Taken together, these results highlight the importance of continued defibrotide therapy until resolution of VOD/SOS signs and symptoms, as currently indicated in the approved product labels, which may occur beyond the recommended minimum of 21 days.
format Online
Article
Text
id pubmed-8549529
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-85495292021-10-27 Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation Richardson, Paul G. Smith, Angela R. Kernan, Nancy A. Lehmann, Leslie Ryan, Robert J. Grupp, Stephan A. Transplant Cell Ther Article Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication that occurs after hematopoietic cell transplantation (HCT). The mortality associated with untreated VOD/SOS with multiorgan dysfunction (MOD) has been reported to be >80%. The recommended dose of defibrotide is 6.25 mg/kg every 6 hours, administered as a 2-hour i.v. infusion, for a minimum of 21 days or until resolution of VOD/SOS signs and symptoms. The objective of this analysis was to evaluate the time to complete response (CR) in patients with post-HCT VOD/SOS treated with defibrotide. The time to defibrotide discontinuation due to a CR served as a surrogate for time to CR in an expanded access study (T-IND; ClinicalTrials.gov NCT00628498; n = 1000), and was analyzed separately from the time to CR data pooled from a phase 2 randomized dose-finding study (NCT00003966; n = 74 patients who received 25 mg/kg/day) and a phase 3 historically controlled study (NCT00358501; n = 102). For all studies, a CR was defined as total serum bilirubin <2 mg/dL with resolution of VOD/SOS-related MOD (renal and/or pulmonary dysfunction); the phase 2 study also required resolution of central nervous system dysfunction. In the T-IND, 390 patients discontinued treatment due to a CR and had sufficient data for analysis. The median time to discontinuation was 22 days (range, 2 to 64 days). Discontinuation due to CR occurred beyond 21 days in 235 patients (60%) and beyond 28 days in 57 patients (15%). The pooled phase 2 and 3 studies included 60 patients who achieved a CR, with a median time to CR of 24.5 days (range, 7 to 123 days). A CR was achieved beyond 21 days in 32 patients (53%) and beyond 28 days in 24 patients (40%). The Kaplan-Meier estimate of day +100 survival rate was substantially higher in patients who discontinued due to a CR compared with those who did not (92.5% versus 37.3%). Treatment-emergent adverse events occurred in 185 of 390 patients (47%) who discontinued due to a CR in the T-IND and in 55 of 60 patients (92%) who achieved a CR in the pooled phase 2 and 3 studies, and rates did not differ according to duration of treatment (≤21 days versus >21 days). Taken together, these results highlight the importance of continued defibrotide therapy until resolution of VOD/SOS signs and symptoms, as currently indicated in the approved product labels, which may occur beyond the recommended minimum of 21 days. 2020-09-17 2021-01 /pmc/articles/PMC8549529/ /pubmed/32950693 http://dx.doi.org/10.1016/j.bbmt.2020.09.008 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Article
Richardson, Paul G.
Smith, Angela R.
Kernan, Nancy A.
Lehmann, Leslie
Ryan, Robert J.
Grupp, Stephan A.
Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation
title Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation
title_full Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation
title_fullStr Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation
title_full_unstemmed Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation
title_short Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation
title_sort analysis of time to complete response after defibrotide initiation in patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic cell transplantation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549529/
https://www.ncbi.nlm.nih.gov/pubmed/32950693
http://dx.doi.org/10.1016/j.bbmt.2020.09.008
work_keys_str_mv AT richardsonpaulg analysisoftimetocompleteresponseafterdefibrotideinitiationinpatientswithhepaticvenoocclusivediseasesinusoidalobstructionsyndromeafterhematopoieticcelltransplantation
AT smithangelar analysisoftimetocompleteresponseafterdefibrotideinitiationinpatientswithhepaticvenoocclusivediseasesinusoidalobstructionsyndromeafterhematopoieticcelltransplantation
AT kernannancya analysisoftimetocompleteresponseafterdefibrotideinitiationinpatientswithhepaticvenoocclusivediseasesinusoidalobstructionsyndromeafterhematopoieticcelltransplantation
AT lehmannleslie analysisoftimetocompleteresponseafterdefibrotideinitiationinpatientswithhepaticvenoocclusivediseasesinusoidalobstructionsyndromeafterhematopoieticcelltransplantation
AT ryanrobertj analysisoftimetocompleteresponseafterdefibrotideinitiationinpatientswithhepaticvenoocclusivediseasesinusoidalobstructionsyndromeafterhematopoieticcelltransplantation
AT gruppstephana analysisoftimetocompleteresponseafterdefibrotideinitiationinpatientswithhepaticvenoocclusivediseasesinusoidalobstructionsyndromeafterhematopoieticcelltransplantation